 | • レポートコード：MRC2208A0035 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、160ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、世界のインスリン市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、作用機序別（即効性、短時間作用性、中間作用性、プレミックス、長時間作用性）分析、ソース別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、Shanghai Fosun Pharmaceutical Co., Ltd.、Tonghua Dongbao、Eli Lilly and Company、Sanofi、Novo Nordisk A/S、Julphar、Biocon Ltd.、Becton, Dickinson and Company、Ypsomed AG、Biodel, Inc.、B. Braun Melsungen AGなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のインスリン市場規模：作用機序別（即効性、短時間作用性、中間作用性、プレミックス、長時間作用性） ・世界のインスリン市場規模：ソース別 ・世界のインスリン市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Isulin Market – Scope of Report
TMR’s report on the global insulin market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global insulin market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insulin market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the insulin market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global insulin market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global insulin market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global insulin market.
The report delves into the competitive landscape of the global insulin market. Key players operating in the global insulin market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global insulin market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market insulin.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Insulin Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Insulin Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Regulatory Scenario, by Region/globally
5.2. Key Mergers & Acquisitions
5.3. Technological Advancements
5.4. COVID-19 Pandemics Impact on Industry
6. Global Insulin Market Analysis and Forecast, by Mode of Action
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Mode of Action, 2017–2031
6.3.1. Rapid-acting
6.3.2. Short-acting
6.3.3. Intermediate-acting
6.3.4. Premixed
6.3.5. Long-acting
6.4. Market Attractiveness Analysis, by Mode of Action
7. Global Insulin market Analysis and Forecast, by Source
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Source, 2017–2031
7.3.1. Modern Insulin
7.3.2. Human Insulin
7.4. Market Attractiveness Analysis, by Source
8. Global Insulin market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Mode of Action, 2017–2031
9.2.1. Rapid-acting
9.2.2. Short-acting
9.2.3. Intermediate-acting
9.2.4. Premixed
9.2.5. Long-acting
9.3. Market Value Forecast, by Source, 2017–2031
9.3.1. Modern Insulin
9.3.2. Human Insulin
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Mode of Action
9.5.2. By Source
9.5.3. By Country
10. Europe Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Mode of Action, 2017–2031
10.2.1. Rapid-acting
10.2.2. Short-acting
10.2.3. Intermediate-acting
10.2.4. Premixed
10.2.5. Long-acting
10.3. Market Value Forecast, by Source, 2017–2031
10.3.1. Modern Insulin
10.3.2. Human Insulin
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Mode of Action
10.5.2. By Source
10.5.3. By Country/Sub-region
11. Asia Pacific Insulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Mode of Action, 2017–2031
11.2.1. Rapid-acting
11.2.2. Short-acting
11.2.3. Intermediate-acting
11.2.4. Premixed
11.2.5. Long-acting
11.3. Market Value Forecast, by Source, 2017–2031
11.3.1. Modern Insulin
11.3.2. Human Insulin
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Mode of Action
11.5.2. By Source
11.5.3. By Country/Sub-region
12. Latin America Insulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Mode of Action, 2017–2031
12.2.1. Rapid-acting
12.2.2. Short-acting
12.2.3. Intermediate-acting
12.2.4. Premixed
12.2.5. Long-acting
12.3. Market Value Forecast, by Source, 2017–2031
12.3.1. Modern Insulin
12.3.2. Human Insulin
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Mode of Action
12.5.2. By Source
12.5.3. By Country/Sub-region
13. Middle East & Africa Insulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Mode of Action, 2017–2031
13.2.1. Rapid-acting
13.2.2. Short-acting
13.2.3. Intermediate-acting
13.2.4. Premixed
13.2.5. Long-acting
13.3. Market Value Forecast, by Source, 2017–2031
13.3.1. Modern Insulin
13.3.2. Human Insulin
13.3.3. Infection Treatment
13.3.4. Gas Embolism
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Mode of Action
13.5.2. By Source
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Shanghai Fosun Pharmaceutical Co., Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Analysis
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Tonghua Dongbao
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Analysis
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Eli Lilly and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Analysis
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Analysis
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Novo Nordisk A/S
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Analysis
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Julphar
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Analysis
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Biocon Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Analysis
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Becton, Dickinson and Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Analysis
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Ypsomed AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Analysis
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Biodel Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Analysis
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
14.3.11. B. Braun Melsungen AG
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Analysis
14.3.11.3. Growth Strategies
14.3.11.4. SWOT Analysis
Table 1: Market Snapshot: Global Insulin Market
Table 2: Global Prevalence of Diabetes, by Type
Table 3: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
Table 4: Global Insulin Market Revenue (US$ Mn), by Source, 2017–2031
Table 5: Global Insulin Market Revenue (US$ Mn), by Region, 2017–2031
Table 6: North America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
Table 7: Europe Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
Table 8: Asia Pacific Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
Table 9: Latin America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
Table 10: Middle East & Africa Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031